Strong show of faith in new direction for microbiome therapies
Summary
It has been a challenging first quarter for biotech financing, but a company founded by British clinical-stage biopharma firm PureTech Health (LSE: PRTC) has secured over $100 million for its work on the microbiome.Cambridge, USA-based Vedanta Biosciences wants to create a new category of oral therapies based on defined bacterial consortia.The company has raised the money to support what could be pivotal development work on its lead candidate, VE303,
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected